UniQure (NASDAQ:QURE), Tocagen (NASDAQ:TOCA), Iovance Biotherapeutics (NASDAQ:IOVA) and Miragen Therapeutics (NASDAQ:MGEN) all resumed with Buy ratings at B. Riley FBR.
Capricor Therapeutics (NASDAQ:CAPR) maintained at Buy at H.C. Wainwright. Price target lowered to $3.50 (846% upside) from $8.60.
Deciphera Pharmaceuticals (NASDAQ:DCPH) upgraded to Buy with a $34 (65% upside) price target at B. Riley FBR.
Applied DNA Sciences (NASDAQ:APDN) downgraded to Hold at Maxim Group. Shares up 12% premarket.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.